Pretransplant Donor-Specific Anti-HLA Antibodies and the Risk for Rejection-Related Graft Failure of Kidney Allografts

Table 2

Characteristics of acute rejection and graft failure within the first 3 months after transplantation for recipients stratified for donor-specific antibodies for HLA.

	No pretransplant DSA (n = 574)	Pretransplant DSA (n = 160)	value
Number of TCMR	102	31	0.64
Number of ABMR	0	5	0.0005
Total number of graft losses	30 (5.2%)	15 (9.4%)	0.06
Primary nonfunctioning graft	18 (3.1%)	12 (7.5%)	0.02
Causes of graft loss
Death with functioning graft	8 (1.4%)	2 (1.2%)	>0.99
Vasculitis	10 (1.7%)	5 (3.1%)	0.33
Vasculitis with thrombi in arterioles	1 (0.2%)	3 (1.9%)	0.03
Vasculitis with tubulointerstitial rejection	7 (1.2%)	0 (0.0%)	0.35
Thrombi/TMA without vasculitis	1/0 (0.2%)	4/1 (3.1%)	0.002
Renal vein/artery thrombosis	3/1 (0.7%)	1 (0.6%)	>0.99
Acute tubular necrosis	2 (0.5%)	1 (0.6%)	>0.99
Others	3 (0.5%)	1 (0.6%)	>0.99
Surgery-related complications	2 (0.3%)	0 (0.0%)	>0.99

DSA: donor-specific anti-HLA antibodies; TCMR: T cell-mediated rejection; ABMR: antibody-mediated rejection; TMA: thrombotic microangiopathy.